Brand drug nam­ing faces chal­lenges in emerg­ing cat­e­gories, ex­pert says

As brand drug nam­ing gets more dif­fi­cult, some ther­a­py ar­eas like obe­si­ty and Alzheimer’s dis­ease are fac­ing even more chal­lenges. That’s be­cause both are tra­di­tion­al­ly more con­ser­v­a­tive cat­e­gories when it comes to the kinds of names the FDA will al­low.

Hint­ing at ben­e­fits, or even sub­tle im­pli­ca­tions, such as weight loss or mem­o­ry gain, are par­tic­u­lar­ly frowned up­on, said Brand In­sti­tute’s pres­i­dent of cre­ative, Scott Pier­grossi.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.